Clinical Trial Update: Nicotine Lozenge to Reduce Smokeless Tobacco Use [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial tested a nicotine lozenge for reducing smokeless tobacco use in individuals with tobacco use disorder; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tobacco Use Disorder

Drugs mentioned

• Nicotine lozenge (nicotine lozenge)

Snippet

Sponsor: National Institute on Drug Abuse (NIDA) | Conditions: Tobacco Use Disorder | Phase 2 | Status: COMPLETED